Combination immunotherapy and internal radiation for recurrent cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new combination treatment for cervical cancer that has come back or spread after standard therapy. It combines an immunotherapy drug (AK104) with a type of internal radiation (I-125 brachytherapy) to see if it can shrink tumors and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cervical cancer that has come back or spread to other areas after prior treatment, and the tumor is in a spot that can be treated with local radiation
- You are between 18 and 70 years old
- You are able to take care of yourself (ECOG score 0-1) and have a life expectancy of more than 3 months
- You have not had immunotherapy or other cancer treatments in the past 4 weeks
- You do not have a serious autoimmune disease, active infection, or major heart, lung, or bleeding problems
- Your organs are working well enough (based on blood tests) and you are willing to use birth control if you could become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding immunotherapy to chemotherapy, then giving chemotherapy together with radiation, works better for advanced cervical cancer. It aims to improve cancer control and help people live longer, without major safety issues.
This study tests whether combining immunotherapy with chemotherapy, followed by radiation plus immunotherapy, can work better than standard treatment for cervical cancer. It aims to help patients whose cancer has not spread yet.
This trial tests a new combination treatment for cervical cancer that has come back or spread. It may be an option for people who have not had previous systemic therapy for this stage of cancer.
This trial tests whether a combination of chemotherapy and immunotherapy (pembrolizumab) before surgery works better than standard chemoradiation for locally advanced cervical cancer. It may help shrink tumors more effectively.
This Phase 1 study tests whether KRC-01, given by injection into the tumor, is safe and tolerable when combined with standard chemoradiation for locally advanced cervical cancer. It also looks for early signs that the treatment can shrink tumors.
This trial tests a new combination of two immunotherapy drugs plus chemotherapy (with or without an anti-VEGF drug) followed by standard chemoradiation for women with advanced cervical cancer that hasn't spread beyond the pelvis. It aims to see if this approach can shrink tumors more effectively than standard treatment alone.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.